1Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to the protocols of the German Multicenter Study Group for Adult ALL (GMALL) , Hematol Oncol Clin North Am, 2000, 14(6):1307-1325.
2Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the G1MEMA ALL 0288 randomized study. Blood, 2002, 99 (3) : 863-871.
4Sotomayer EM, Piantadosi S, Miller CB, et al. Long-term follow-up of intensive Ara-C based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastie leukemia: impact of induction Ara-C dose and postremission therapy, Leuk Res, 2002, 26(5): 461-471.
5Wiernik PH, Cassileth PA, Leong T, et al. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine)in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486) Leuk Lymphoma, 2003,44(9): 1515-1521.
6Kantarjian HM, O' Brien S, Smith TL, et al. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. J Clin Oncol, 9000, 18(3): 547-561.
7Attal M. Blaise D, Marit G, et al. Consolidative treatment of adult acute lymphoblastie leukemia: a prospective, randomized trial comparing allogenele versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood, 1995, 86(4): 1619-1628.
8Vey N, Blaise D, Stoppa A, et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant, 1994, 14(3): 383-388.
9Thiebault A, Vernant JP, Degos 1,, et ah Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am, 2000, 14(6): 1353-1366.
10Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL 93 study, Leukemia, 2002,16(7): 1259-1266.
6Pui CH,Evans WE.Treatment of acute lymphoblasfic leukemia[J].N Engl J Med,2006,354(2):166-178.
7Thomas X,Boiron JM,Huguet F,et al.Outcome of treatment in adults with acute lymphoblastic leukemia:analysis of the LALA-94 trial[J].J Clin Oncol,2004,22(20):4075-4086.
8Ottmann OG.Wassmann B,Pfeifer H,et al.Imatinib compared withchemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblasticleukemia (Ph+ ALL)[J].Cancer,2007,109(10):2068-2076.
9Bruggemann M,Raff T,Flohr T,et al.Clinical signifycance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia[J].Blood,2006,107(3):1116-1123.
10Woessmann W.Seidemann K.Mann G,et al.The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms:a report of the BFM Group Study NHL-BFM95[J].Blood,2005,105(3):948-958.
